Genetics Generation Advancement Corp. AI Stock Analysis
Genetics Generation Advancement Corp. (4160) AI Stock Analysis
Genetics Generation Advancement Corp.
(TPEx:4160)
The score is held back primarily by weakening financial performance: revenue declined ~9%, operating margin collapsed to 2.0%, net income fell ~61%, and the company swung to negative operating and free cash flow despite reporting a profit. The fortress-like balance sheet — 75% equity-funded assets and minimal leverage — provides meaningful downside protection and funding flexibility, which is the main support for the score. Technicals are negative, with the price below all major moving averages and a bearish MACD, although deeply oversold readings suggest the selling may be stretched. Valuation is mixed: a high P/E of 50.3 on depressed earnings is unattractive, while the 5.27% dividend yield is appealing but faces questions given the recent cash burn. Overall, the stock looks financially stable but operationally fragile, warranting a below-average score until cash generation and margins recover.
Genetics Generation Advancement Corp. (4160) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 1.00B
- Dividend Yield
- 4.93%
- Average Volume (3M)
- 32.70K
- Price to Earnings (P/E)
- 52.8
- Beta (1Y)
- 0.49
- Revenue Growth
- 0.10%
- EPS Growth
- -44.49%
- Country
- TW
- Employees
- 169
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Diagnostics & Research
Genetics Generation Advancement Corp. Business Overview & Revenue Model
Company Description
Genetics Generation Advancement Corp. (GGAC), headquartered in Taipei, Taiwan, specializes in providing advanced genetic testing and bioinformatics solutions. The company serves a diverse global clientele across Taiwan, Asia, Europe, and the Americas...
Genetics Generation Advancement Corp. Financial Statement Overview
Summary
A very strong balance sheet (equity funds ~75% of assets, debt-to-equity of just 0.13) is offset by deteriorating operations. The latest year saw revenue fall ~9% to NT$603 million, operating margin compress from 10.3% to 2.0%, and net income drop ~61%. Most concerning, cash generation swung from NT$82 million of operating cash flow to an NT$18 million outflow, with free cash flow at negative NT$50 million, meaning reported profit was not converted into cash. Longer-term trends (multi-year revenue growth, gross margin expansion from ~32% to 40-42%) remain constructive, but current earnings quality and cash conversion are the key weak spots.
Income Statement
47NeutralBalance Sheet
76PositiveCash Flow
33Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 614.42M | 603.11M | 661.86M | 592.50M | 547.81M | 519.51M |
| Gross Profit | 253.79M | 250.44M | 280.01M | 236.83M | 226.44M | 195.49M |
| EBITDA | 29.61M | 37.22M | 85.95M | 50.60M | 44.01M | 20.48M |
| Net Income | 17.98M | 21.46M | 54.70M | 28.57M | 25.73M | 7.84M |
Balance Sheet | ||||||
| Total Assets | 717.86M | 806.05M | 724.30M | 595.05M | 455.66M | 424.76M |
| Cash, Cash Equivalents and Short-Term Investments | 320.81M | 408.95M | 414.48M | 315.61M | 259.24M | 200.57M |
| Total Debt | 126.53M | 80.08M | 41.19M | 49.30M | 3.33M | 2.42M |
| Total Liabilities | 224.20M | 204.05M | 170.81M | 164.91M | 108.20M | 106.06M |
| Stockholders Equity | 493.08M | 601.55M | 553.13M | 429.94M | 347.46M | 318.92M |
Cash Flow | ||||||
| Free Cash Flow | -35.90M | -49.64M | 55.61M | 61.74M | 43.67M | -3.11M |
| Operating Cash Flow | -140.00K | -18.33M | 81.62M | 66.86M | 51.81M | 7.32M |
| Investing Cash Flow | -40.90M | -26.34M | -60.42M | -7.80M | -71.52M | 10.19M |
| Financing Cash Flow | 40.44M | -18.51M | -20.96M | 12.25M | -7.80M | -751.00K |
Genetics Generation Advancement Corp. Peers Comparison
Overall Rating
- TW:416049Neutral
TW:417140Underperform
Financial Indicators
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4160 | Genetics Generation Advancement Corp. | 35.70 | -15.27 | -29.96% | |
| TW:4171 | GeneReach Biotechnology Corp. | 15.45 | -6.75 | -30.41% | |
| TW:6539 | DV Biomed Co., Ltd. | 36.20 | -17.44 | -32.52% | |
| TW:6810 | Bio Preventive Medicine Corp. | 21.95 | -2.75 | -11.13% | |
| TW:6879 | Tci Gene Inc. | 35.50 | -3.65 | -9.32% | |
| TW:7725 | LabTurbo Biotech Corporation | 21.00 | -3.30 | -13.57% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026